Skip to main content
FDA Shortage Check

Is Saxenda (Liraglutide Injection) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Saxenda: in shortage (FDA, Oct 24)

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Delay in shipping of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Discontinuation of the manufacture of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
DRUG
Saxenda
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
Jul 18, 2023
LAST FDA UPDATE
Oct 14, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 9 presentations: 0 unavailable · 3 limited · 6 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Liraglutide Injection. 11 presentations from 4 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Novo Nordisk, Inc.5 presentations · 3 limited · 2 available or not stated

Contact (FDA's listing): 833-493-4689

  • 6 mg/1 mL

    Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)

    Product will be available until discontinuation in January 2027

    NDC 0169-2800-15Reverified

    Limited Availability

  • 6 mg/1 mL

    Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)

    Estimated shortage duration: TBD

    NDC 0169-4060-12Reverified

    Limited Availability

  • 6 mg/1 mL

    Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)

    Estimated shortage duration: TBD

    NDC 0169-4060-13Reverified

    Limited Availability

  • 6 mg/1 mL

    Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)

    Distributed by Teva

    NDC 0480-3667-20Reverified

    Available

  • 6 mg/1 mL

    Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)

    Distributed by Teva

    NDC 0480-3667-22Reverified

    Available

Hikma Pharmaceuticals USA, Inc.2 presentations · 2 available or not stated

Contact (FDA's listing): 800-631-2174

  • 6 mg/1 mL

    Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)

    NDC 0143-9144-02Reverified

    Available

  • 6 mg/1 mL

    Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)

    NDC 0143-9144-03Reverified

    Available

Meitheal Pharmaceuticals, Inc.2 presentations · 2 available or not stated

Contact (FDA's listing): 844-824-8426

  • 6 mg/1 mL

    Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)

    NDC 71288-563-84Revised

    Available

  • 6 mg/1 mL

    Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)

    NDC 71288-563-85Revised

    Available

What the manufacturers told FDA

  • Novo Nordisk, Inc. · ‘Estimated shortage duration: TBD’ · updated Sep 2026
  • Novo Nordisk, Inc. · ‘Product will be available until discontinuation in January 2027’ · updated Sep 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Delay in shipping of the drug
  • Discontinuation of the manufacture of the drug

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Other products with the same ingredient and form

A discontinuation “does not necessarily create a shortage” (FDA).

  • Novo Nordisk, Inc. told FDA it will discontinue Saxenda (posted ).

    “Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug”

    FDA listing: Liraglutide Injection

  • Teva Pharmaceuticals USA, Inc. told FDA it will discontinue Liraglutide (posted ).

    “Discontinuation of the manufacture of the drug”

    FDA listing: Liraglutide Injection

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Saxenda in shortage?
Yes. As of Oct 24, 2026, FDA lists Liraglutide Injection as currently in shortage: 9 presentations, 0 unavailable and 3 limited.
When will the Saxenda shortage end?
FDA gives no end date, and no manufacturer posted a recovery estimate for this listing.
Does FDA list alternatives to Saxenda?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.